We determined that ACAT1 can regulate the MAPK signalling pathway; therefore, we believe that SIRT5 regulates the MAPK signalling pathway through ACAT1, thereby promoting prostate cancer. This evidence concerns the gene SIRT5 and prostate carcinoma.